Serotonergic gene variation in substance use pharmacotherapy: a systematic review.
Serotonergic gene variation in substance use pharmacotherapy: a systematic review.
复制标题
DOI：
10.2217/pgs.15.72
复制
发表时间：
2015
期刊：
影响因子：
2.1
通讯作者：
Nielsen DA
中科院分区：
文献类型：
--
作者：
Bauer IE;Graham DP;Soares JC;Nielsen DA
吸毒是一种严重的疾病，对大脑和身体健康都有破坏性的影响。尽管受影响的个人数量有所增加，但针对物质使用障碍的有效药物治疗选择寥寥无几。研究个体的遗传特征对治疗反应的影响可能有助于确定更有效的治疗方案。这篇系统的综述集中在5-羟色胺能系统，因为它在情绪和冲动控制障碍中的相关作用，以及它在药物使用障碍的发展和维持中的贡献。特别是，我们研究了5-羟色胺能基因在酒精、可卡因和尼古丁成瘾药物治疗反应中的作用。目前的证据表明，5-羟色胺能生物合成酶色氨酸羟化酶2(TPH2)和5-羟色胺转运体(SLC6A4)基因的遗传变异性介导了几种成瘾治疗方法的疗效，如恩丹西酮和双硫仑，以及抗抑郁药安非他酮、去甲替林和舍曲林。
Drug addiction is a serious disease with damaging effects on the brain and physical health. Despite the increase in the number of affected individuals, there are few effective pharmacological treatment options for substance use disorders. The study of the influence of an individual's genetic features on the treatment response may help to identify more efficacious treatment options. This systematic review focuses on the serotonergic system because of its relevant role in mood and impulse control disorders, and its contribution to the development and maintenance of drug use disorders. In particular, we examine the role of serotonergic genes in the response to pharmacotherapy for alcohol, cocaine and nicotine addiction. Current evidence suggests that genetic variability of the serotonergic biosynthesis enzyme tryptophan hydroxylase 2 (TPH2) and the serotonin transporter (SLC6A4) genes mediates the efficacy of several addiction treatments, such as ondansetron and disulfiram, and the antidepressants bupropion, nortriptyline and sertraline.